

## Product datasheet for **TL308768V**

### CEMIP2 Human shRNA Lentiviral Particle (Locus ID 23670)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CEMIP2 Human shRNA Lentiviral Particle (Locus ID 23670)
Locus ID:	23670
Synonyms:	TMEM2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	TMEM2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_001135820</a> , <a href="#">NM_013390</a> , <a href="#">NM_001349784</a> , <a href="#">NM_013390.1</a> , <a href="#">NM_013390.2</a> , <a href="#">NM_001135820.1</a> , <a href="#">BC140773</a> , <a href="#">BC044850</a> , <a href="#">BC144510</a> , <a href="#">BC146780</a> , <a href="#">BC171782</a> , <a href="#">NM_013390.3</a> , <a href="#">NM_001135820.2</a>
UniProt ID:	<a href="#">Q9UHN6</a>
Summary:	This gene encodes a type II transmembrane protein that belongs to the interferon-induced transmembrane (IFITM) protein superfamily. The encoded protein functions as a cell surface hyaluronidase that cleaves extracellular high molecular weight hyaluronan into intermediate size fragments before internalization and degradation in the lysosome. It also has an interferon-mediated antiviral function in humans through activation of the JAK STAT signaling pathway. The activation of this gene by transcription factor SOX4 in breast cancer cells has been shown to mediate the pathological effects of SOX4 on cancer progression. Naturally occurring mutations in this gene are associated with autosomal recessive non-syndromic hearing loss. [provided by RefSeq, Mar 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).